X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Keytruda (Pembrolizumab) is a PD-1 inhibitor antibody drug candidate, which is currently being evaluated in cmbination with lenvatinib for the first-line treatment of patients with advanced or recurrent endometrial carcinoma.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is DNA inhibitor. It is being evaluated under phase 1/2 clinical development in combination with Lenvima (lenvatinib) for the treatment of hepatocellular carcinoma.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
LENVIMA (lenvatinib) capsule is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the VEGF receptors and is being evaluated in combination with pembrolizumab in patients with Metastatic Non-Small Cell Lung Cancer.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2023
Details:
LENVIMA (lenvatinib) Capsule is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the VEGF receptors and evaluating in combination with pembrolizumab in patients With metastatic head and neck squamous cell carcinoma.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
Lenshil (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Lead Product(s): Lenvatinib
Therapeutic Area: Oncology Product Name: Lenshil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
Lenvima® (lenvatinib), discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
AIV007 is a novel formulation using our JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis.
Lead Product(s): Lenvatinib
Therapeutic Area: Ophthalmology Product Name: AIV007
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
The decision is based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data from a planned interim analysis and determined KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) did not demonstrate an improvement in overall survival.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug. Its active metabolite troxacitabine triphosphate (TRX-TP) is then incorporated into rapidly dividing cancer cell's DNA, thereby causing DNA damage and cancer cell death.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
Lenvima (lenvatinib) is a RTK inhibitor that inhibits the kinase activities of VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). It also inhibits pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Final analyses of the RWD study showed that 72.4% of patients treated with LENVIMA (Lenvatinib), a multiple receptor tyrosine kinase inhibitor had Best Overall Response (BOR) reported as a complete (26.9%) or partial (45.5%) response.
Lead Product(s): Lenvatinib
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
In final analysis, there was improvement for one of dual primary endpoints, overall survival, for patients treated with Lenvima (Lenvatinib) plus KEYTRUDA versus Lenvima monotherapy; however, results did not meet statistical significance per pre-specified statistical plan.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
In final analysis of trial, study’s dual primary endpoints, overall survival, for patients treated with KEYTRUDA (pembrolizumab) plus LENVIMA versus LENVIMA monotherapy; however, results did not meet statistical significance per the pre-specified statistical plan.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the clinical benefit of lenvima (lenvatinib) plus pembrolizumab and the combination’s potential across difficult-to-treat cancers.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
The VENTANA MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (dMMR), and who may be eligible for KEYTRUDA® (pembrolizumab).
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
Data from trial investigating KEYTRUDA (pembrolizumab), plus LENVIMA, versus LENVIMA monotherapy did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for patients with hepatocellular carcinoma.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
The approval is based on results from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE581 trial, in which LENVIMA plus KEYTRUDA demonstrated statistically significant improvements versus sunitinib in the primary efficacy outcome measure of progression-free survival (PFS).
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
Results from CLEAR/KEYNOTE-581 showed KEYTRUDA plus LENVIMA signicantly reduced the risk of disease progression or death by 61%, with a median progression-free survival of nearly two years versus nine months for sunitinib.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
The approval is based on results from the CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination of LENVIMA plus KEYTRUDA, for the first-line treatment of patients with advanced RCC.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
Details:
Results showed that the KEYTRUDA plus LENVIMA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival and progression-free survival compared to chemotherapy.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
Administration of LENVIMA plus KEYTRUDA was permitted beyond RECIST-defined disease progression if the treating investigator considered the patient to be deriving clinical benefit and the treatment was tolerated.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
MHLW approval marks first time combination of KEYTRUDA plus LENVIMA approved in Japan, is based on results from pivotal Phase 3 KEYNOTE-775/Study 309 trial, where data demonstrated statistically significant improvements in overall survival and reducing risk of death.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2021
Details:
First patient dosed with MIV-818 currently in the phase 1b/2a for the treatment of hepatocellular carcinoma, the purpose of the study is to evaluate safety, tolerability and also to get an indication of the efficacy.
Lead Product(s): MIV-818,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Approval Based on Results From CLEAR/KEYNOTE-581 trial Demonstrating KEYTRUDA Plus LENVIMA Significantly Reduced the Risk of Disease Progression or Death by 61% and ORR was 71% for patients treated with KEYTRUDA plus LENVIMA.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
Patients treated with KEYTRUDA plus LENVIMA achieved a complete response (CR) rate of 7% and partial response (PR) rate of 25% versus a CR rate of 3% and a PR rate of 12% for patients treated with chemotherapy.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
E7386 is a CBP/β-catenin inhibitor that inhibits CBP and β-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression is expected to suppress tumor.
Lead Product(s): E7386,Lenvatinib
Therapeutic Area: Oncology Product Name: E7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: PRISM BioLab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
In the study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point inhibitor.
Lead Product(s): MIV-818,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
Among the 697 not dMMR patients, 346 patients were randomized to KEYTRUDA plus LENVIMA, and 351 patients were randomized to investigator's choice of doxorubicin (n=254) or paclitaxel (n=97).
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
The combination of lenvatinib and everolimus showed increased anti-angiogenic and anti-tumor activity as demonstrated by decreases in human endothelial cell proliferation, tube formation, and VEGF signaling in vitro.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
The applications in advanced RCC are based on results from the CLEAR study (KEYNOTE-581/Study 307), in which KEYTRUDA plus LENVIMA demonstrated statistically significant improvements in PFS, OS and ORR versus sunitinib.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
KEYTRUDA Plus LENVIMA significantly reduced the risk of death by 38%, with a median overall survival of 18.3 months versus 11.4 months with chemotherapy regardless of mismatch repair status.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eisai Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
KEYTRUDA Plus LENVIMA significantly reduced risk of disease progression or death by 61% versus sunitinib, with a median PFS of nearly two years versus nine months for sunitinib.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2021
Details:
Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimus.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
Data on the lenvatinib, pembrolizumab combination that will be presented includes results from the Phase 2 LEAP-005 trial of multiple cohorts of patients with previously treated solid tumors, including: gastric cancer, biliary tract cancers and colorectal cancer.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
Based on an analysis conducted by an independent Data Monitoring Committee, KEYTRUDA plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in OS, PFS and ORR versus chemotherapy.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
New safety and efficacy data on LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, will be presented from two trials in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
Lead Product(s): Lenvatinib
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
CLEAR is a multi-center, randomized, open-label, Phase 3 trial evaluating LENVIMA in combination with KEYTRUDA or in combination with everolimus versus sunitinib alone for the first-line treatment of patients with advanced RCC.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE).
Lead Product(s): Lenvatinib,Everolimus
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
In the Phase 2 LEAP-005 trial, KEYTRUDA plus LENVIMA demonstrated an ORR that ranged from 9.7-32.3% in previously treated patients with triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, glioblastoma multiforme and biliary tract cancer.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2020
Details:
Results indicate that the lower starting dose (18 mg) of LENVIMA did not meet the non-inferiority requirement compared to the approved starting dose (24 mg) in patients with RAI-refractory DTC.
Lead Product(s): Lenvatinib
Therapeutic Area: Oncology Product Name: Lenvima
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Data highlighted shows continued progress on clinical trials for the KEYTRUDA plus LENVIMA combination across multiple tumor types, including a virtual oral presentation on the Phase 2 results of the metastatic clear cell renal cell carcinoma cohort of a Phase 1b/2 study.
Lead Product(s): Lenvatinib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
The single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus enrolled 31 patients with unresectable advanced or metastatic nccRCC.
Lead Product(s): Lenvatinib,Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
